<div id="readability-page-1"><p>Kidder Stephen W raised its holdings in shares of  Eli Lilly and Company (NYSE:LLY - Free Report) by 92.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,130 shares of the company's stock after acquiring an additional 1,505 shares during the period. Kidder Stephen W's holdings in Eli Lilly and Company were worth $2,440,000 at the end of the most recent quarter.</p><div><p><span></span><span>Get <strong>Eli Lilly and Company</strong> alerts:</span></p></div><ul><li>5 Healthcare Plays Powering the Sector’s Big Comeback</li></ul><p>Other institutional investors have also recently made changes to their positions in the company. Secured Retirement Advisors LLC purchased a new stake in shares of  Eli Lilly and Company during the second quarter worth $1,103,000.  NBT Bank N A NY increased its stake in shares of  Eli Lilly and Company by 2.2% during the second quarter. NBT Bank N A NY now owns 10,648 shares of the company's stock worth $8,300,000 after buying an additional 229 shares during the period.  Abel Hall LLC increased its stake in  Eli Lilly and Company by 26.0% in the second quarter. Abel Hall LLC now owns 1,121 shares of the company's stock valued at $874,000 after purchasing an additional 231 shares during the last quarter.  Somerville Kurt F increased its stake in  Eli Lilly and Company by 72.2% in the second quarter. Somerville Kurt F now owns 7,242 shares of the company's stock valued at $5,645,000 after purchasing an additional 3,036 shares during the last quarter.  Finally, Proffitt &amp; Goodson Inc. boosted its holdings in shares of  Eli Lilly and Company by 2,021.2% in the second quarter. Proffitt &amp; Goodson Inc. now owns 700 shares of the company's stock valued at $546,000 after acquiring an additional 667 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors. </p><h2>Analyst Ratings Changes</h2><p>Several research firms have recently commented on LLY. JPMorgan Chase &amp; Co. reduced their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an &#34;overweight&#34; rating for the company in a research note on Tuesday, September 16th. Morgan Stanley lowered their price target on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an &#34;overweight&#34; rating for the company in a report on Friday. Leerink Partnrs lowered Eli Lilly and Company from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Thursday, August 7th. Cantor Fitzgerald cut their target price on Eli Lilly and Company from $975.00 to $825.00 and set an &#34;overweight&#34; rating on the stock in a research report on Wednesday, August 13th. Finally, UBS Group lowered their price target on Eli Lilly and Company from $1,050.00 to $895.00 and set a &#34;buy&#34; rating for the company in a report on Friday, August 8th. One analyst  has rated the stock with a Strong Buy rating, fourteen have assigned  a Buy rating and ten have assigned  a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $938.94.</p><ul><li>Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal</li></ul><p><b>Get Our Latest Research Report on Eli Lilly and Company</b></p><h2>Eli Lilly and Company Stock Performance</h2><p>LLY stock opened at $844.30 on Wednesday. The firm has a market cap of $799.09 billion, a PE ratio of 55.18, a P/E/G ratio of 1.18 and a beta of 0.47. The business's 50-day moving average price is $736.97 and its two-hundred day moving average price is $766.03. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $937.00. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. </p><ul><li>Trump’s Drug Price Cuts: Boom or Bust for These 3 Pharma Giants</li></ul><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business's revenue for the quarter was up 37.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.92 earnings per share.  Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, research analysts forecast that  Eli Lilly and Company will post 23.48 earnings per share for the current year. </p><h2>Insider Buying and Selling at Eli Lilly and Company</h2><p>In other Eli Lilly and Company news, CEO David A. Ricks bought 1,632 shares of the stock in a transaction on Tuesday, August 12th. The shares were acquired at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the acquisition, the chief executive officer directly owned 546,601 shares of the company's stock, valued at $352,431,926.77. The trade was a 0.30% increase in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Also, Director J Erik Fyrwald purchased 1,565 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the transaction, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. This represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased 4,514 shares of company stock worth $2,894,841 over the last 90 days. Company insiders own  0.14% of the company's stock. </p><h2>Eli Lilly and Company Company Profile</h2> (Free Report)<p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Eli Lilly and Company</li><li>How to Know if a Stock Pays Dividends and When They Are Paid Out</li><li>EA’s $55 Billion Deal Spurs a Shake-Up in the Gaming Sector</li><li>What Are Dividend Contenders? Investing in Dividend Contenders</li><li>These Are the 3 Hottest Sectors for Q3 Earnings Growth</li><li>The Role Economic Reports Play in a Successful Investment Strategy</li><li>AMD Could Double From Here—Thanks to Its Blockbuster OpenAI Deal</li></ul><p><strong>Want to see what other hedge funds are holding LLY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Kidder Stephen W increased its stake in Eli Lilly and Company (NYSE: LLY) by 92.6% in Q2, now holding 3,130 shares valued at $2.44 million. Other institutional investors also adjusted their positions. Analysts have mixed ratings on LLY, with target prices ranging from $825 to $1,050. The stock opened at $844.30, with a market cap of $799.09 billion and a PE ratio of 55.18. Eli Lilly reported strong Q2 earnings, exceeding estimates with $6.31 EPS and $15.56 billion in revenue, a 37.6% increase year-over-year.</p>

Kidder Stephen W Grows Stock Holdings in Eli Lilly and Company $LLY